Clinical Trial Finder
The Celiac Disease Foundation Clinical Trial Finder was created to help people with celiac disease and non-celiac gluten/wheat sensitivity, and healthy controls (people who do not have the disease), participate in clinical trials to accelerate the development of drugs and treatments. With up to 50% of patients continuing to experience symptoms and/or intestinal damage while on the gluten-free diet, finding a better treatment is crucial.
The purpose of a clinical trial is to determine the most effective and safest treatment for a disease. Clinical trials are a vital component of U.S. Food and Drug Administration’s drug approval process, without which advances in therapeutics for celiac disease patients are not possible. Your participation can end the needless suffering for generations to come.
Finding a Trial
The information returned from your search has been obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
See if you qualify for a current Seattle-based study to advance treatments for cross-contact with gluten by filling out the screening survey.
Do you need volunteers for your clinical trial? Find them with iCureCeliac®. Contact us at firstname.lastname@example.org to get started.
Acute Abdomen in Adults- a Prospective Study on Emergency Department Admissions
This is a non-randomized, prospective, population-based, single-center study designed to evaluate conditions resulting emergency admission in patients with abdominal pain. Furthermore, we are interested in how many patients are discharged with "non-specific abdominal pain" but later readmitted and diagnosed with a specific diagnosis.18 Years and Over
Antibody Treatment for Advanced Celiac Disease
Background: - Celiac disease is a condition where the immune system attacks the cells of the small intestine. The intestine becomes inflamed and cannot digest food properly. The disease most often causes a reaction to foods that contain gluten. Most people can treat celiac disease with a gluten-free diet. However, some people have digestion problems even on a gluten-free diet. Researchers want to try a new antibody therapy for celiac disease. The treatment may block the immune reaction that causes the disease. They will test this antibody in people who have celiac disease that has not responded to a gluten-free diet. Objectives: ...18 Years and Over
A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease
To assess the efficacy and safety of AGY vs placebo when administered to individuals age 10 to 65 years with medically proven CD and on a gluten free diet10 Years - 65 Years
Assessment of Adherence to Gluten Free Diet in Children and Adolescents by Detection of Gluten in Faecal Samples.
To assess the adherence to gluten free diet by measuring faecal and urinary gluten immunogenic peptides (GIP). This will provide an objective measure for adherence.2 Years - 17 Years
Assessment of Immune Activation and Tolerance in Celiac Disease
The primary purpose of this study is to characterize changes in gluten-specific T cells and pathology in the small intestine with specific focus on biomarkers likely to change with therapeutic celiac disease (CeD) treatment.18 Years - 75 Years
Assessment of the Effect of Gluten Free Toothpaste on the Ulcerative Events in Children With Celiac Disease
Celiac disease (CD) is the most common genetically based food intolerance in the world, with a prevalence among approximately 1% of the general population (Guandalini & Assiri, 2014). CD is a frequent disorder among Egyptian children, both in the general population and in at-risk groups(Abu-Zekry et al., 2008). It is estimated that the incidence of CD is 3 to13 cases per1000, with a higher prevalence among first-degree relatives of patients with CD.Lifelong adherence to a strict gluten free diet (GFD) remains the only available treatment for patients with CD and typically results in a complete return to health. Nevertheless, gluten is not...6 Years - 15 Years
Assess the Gluten Degradation Activity of PvP001 and PvP002 in Healthy Adult Volunteers
This study has two parts. Each part of the study begins with a Screening Period of up to 4 weeks to allow for completion of screening procedures and subject scheduling. Each subject will be screened by means of medical history, medication review, Gastrointestinal Symptoms Questionnaire (GSQ), physical examination, vital signs, weight, height, laboratory tests, and ECG.18 Years - 59 Years
A Study of the Safety, Efficacy and Tolerability of Nexvax-2 in Patients With Celiac Disease (CeD)
A randomized, double-blind, placebo-controlled clinical study in human leukocyte antigen (HLA)-DQ 2.5+ adults with celiac disease (CeD).18 Years - 70 Years
A Study to Evaluate Gluten Challenge on Immune Responses in Subjects With Celiac Disease
This is a model development, open label, no therapeutic treatment, three sequential group, short term-gluten challenge study in subjects with celiac disease. Immune responses are evaluated following gluten challenge. Approximately fifteen subjects with celiac disease will be enrolled in up to three sequential groups (5 subjects per group).18 Years - 65 Years
Bakery Products for Non-Coeliac Gluten Sensitive Consumers
The aim of the study is to produce a tolerable alternative to normal wheat bread which would be suitable for subjects with self-reported non-coeliac gluten sensitivity (NCGS). The bread would be made from wheat so, in contrast to gluten-free bread, would be more comparable to standard bread. To make this bread, the investigators will use advanced enzyme technology and/or novel formulations to target the digestion or removal of wheat proteins, which might be involved in the etiology of non-coeliac gluten sensitivity, preferentially over other those that are more useful for baking quality. The investigators will determine palatability and...18 Years - 70 Years